Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · June 16, 2022

MRD Response and Outcomes With Fixed-Duration Venetoclax–Rituximab in Relapsed/Refractory CLL

Blood

 

Additional Info

Disclosure statements are available on the authors' profiles:

Blood
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
Blood 2022 May 23;[EPub Ahead of Print], JF Seymour, TJ Kipps, B Eichhorst, J D'Rozario, C Owen, S Assouline, N Lamanna, T Robak, J de la Serna, U Jaeger, G Cartron, M Montillo, C Mellink, B Chyla, A Panchal, T Lu, QJ Wu, Y Jiang, M Lefebure, M Boyer, AP Kater

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading